Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CLN-978

Bispecific antibody · Immune activation, directed at CD19 and CD3 (CD3E) · developed by Cullinan Therapeutics

Phase 1 Most advanced trial
CGEM Developer
1 Registered trials

What is CLN-978?

CLN-978 is a T-cell engaging bispecific antibody that binds CD19 on target cells and CD3 on T-cells, cross-linking the two to induce a cytotoxic T-lymphocyte response against CD19-expressing cells. An albumin-binding domain extends its half-life. It is being studied in Sjögren's syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
CD19, CD3 (CD3E)
Mechanism
Immune activation, directed at CD19 and CD3 (CD3E)
Pathways
T-cell mediated cytotoxicity, cytotoxic T-lymphocyte response
Therapy area
Immunology
Developer
Cullinan Therapeutics Inc. (CGEM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07041099 Phase 1 Sjögren Recruiting CGEM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SjögrenSjogren DiseaseSjogren's Syndrome

Other drugs acting on CD19 / CD3E

More from Cullinan Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.

Follow CGEM, the company behind CLN-978

See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.